Multimodal porogen platforms for calcium phosphate cement degradation by Lodoso-Torrecilla, I. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/205350
 
 
 
Please be advised that this information was generated on 2020-09-10 and may be subject to
change.
Multimodal porogen platforms for calcium phosphate cement
degradation
Irene Lodoso-Torrecilla,1# Eline-Claire Grosfeld,1# Abe Marra,1 Brandon T Smith,2 Antonios G Mikos,2,3
Dietmar JO Ulrich,4 John A Jansen,1 Jeroen JJP van den Beucken1
1Department of Regenerative Biomaterials, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center,
6500 HB Nijmegen, The Netherlands
2Department of Bioengineering, Rice University, Houston, Texas 77030
3Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas 77005
4Department of Plastic & Reconstructive Surgery, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
Received 12 October 2018; revised 20 February 2019; accepted 22 March 2019
Published online 9 April 2019 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.36686
Abstract: Calcium phosphate cements (CPCs) represent excellent
bone substitute materials due to their biocompatibility and
injectability. However, their poor degradability and lack of ma-
croporosity limits bone regeneration. The addition of poly(D,L-lac-
tic-co-glycolic acid) (PLGA) particles improves macroporosity and
therefore late stage material degradation. CPC degradation and
hence, bone formation at an early stage remains challenging, due
to the delayed onset of PLGA degradation (i.e., after 2–3 weeks).
Consequently, we here explored multimodal porogen platforms
based on sucrose porogens (for early pore formation) and PLGA
porogens (for late pore formation) to enhance CPC degradation
and analyzed mechanical properties, dynamic in vitro degradation
and in vivo performance in a rat femoral bone defect model.
Porogen addition to CPC showed to decrease compressive
strength of all CPC formulations; transition of the crystal phase
upon in vitro incubation increased compressive strength. Although
dynamic in vitro degradation showed rapid sucrose dissolution
within 1week, no additional effects on CPC degradation or bone
formation were observed upon in vivo implantation. © 2019 The
Authors. journal Of Biomedical Materials Research Part A Published By
Wiley Periodicals, Inc. J BiomedMater Res Part A: 107A: 1713–1722, 2019.
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INTRODUCTION
Calcium phosphate (CaP)-based bone substitutes are the
most widely used synthetic alternatives for autologous bone
grafts in the field of bone regenerative surgery.1 Clinically,
CaP-based bone substitutes have advantages over autologous
bone in terms of off-the-shelf availability, for which no
restrictions in quantity apply and no extra surgical site to
harvest donor bone is required.
A cement form renders these CaP-based bone substitutes
injectable, allowing such CaP cements (CPCs) to be applied
via minimally invasive surgery and to be molded into the
bone defect for optimal bone defect filling.2,3 Depending on
the end product of the setting reaction, CPCs can be roughly
divided in two categories; apatite or brushite. Of those, most
research has focused on apatitic CPCs due a higher similarity
to the mineral phase of bone and their superior mechanical
properties than brushite CPCs.4,5 Due to their similarity to
the mineral phase of bone, apatitic CPCs possess several
advantageous biological properties, including biocompatibil-
ity, bioactivity, and osteoconductivity.6 However, CPCs have
demonstrated to degrade at a slow rate, limiting the avail-
able space for the formation of new bone; and hence the
complete regeneration of a bone defect.7,8 To overcome this
drawback, multiple types of porogens have been explored as
an additive for CPC,8 of which poly(lactic-co-glycolic-acid)
(PLGA) has demonstrated to be most effective.9 PLGA por-
ogens have a beneficial (hydrolytic) degradation profile,
which generates porosity within the ceramic CPC matrix and
simultaneously accelerates the degradation of this ceramic
CPC matrix via its acidic degradation products (i.e., lactic
and glycolic acid).10 Previous work has shown that chemical
characteristics of PLGA (i.e., acid-terminated or end-capped),
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porogen type (i.e., dense or hollow), and size all influence
the degradation of CPC-PLGA composites.9–11
With the use of PLGA porogens, pore formation within CPC
gradually starts after ~2weeks.12 These pores create ma-
croporosity within the ceramic CPC matrix, which allows for
fluid flow and tissue ingrowth, especially when the created
pores are interconnected.9 Recent in vivo experimental work
using a femoral condyle bone defect model in rabbits compared
the degradation and bone formation of CPC-PLGA with the den-
tal predicate device Bio-Oss®, which is a granulate material
consisting of devitalized bovine bone.13 Although CPC-PLGA
demonstrated superiority regarding material degradation and
bone formation after a prolonged implantation period of
6 months, initial bone formation was delayed. Earlier experi-
mental work using a rat calvarial bone augmentation model, in
which instantaneous porosity was created via a foaming tech-
nique during CPC setting and delayed porosity was created via
inclusion of PLGA porogens, already showed that instantaneous
porosity in CPC is favorable for initiating bone formation.14
These data indicate that further improvement of CPC-porogen
formulations should focus on the inclusion of porogens that
rapidly dissolve or degrade to obtain macroporosity within the
ceramic CPC matrix early after setting.
Alternative materials to function as a fast-acting porogen
within CPC have recently been explored.15,16 Exploration of
especially water-soluble porogens seem appealing15–19 due
to their rapid dissolution. Smith et al.15 showed that glucose
porogens dissolve from within the ceramic CPC matrix
within 3 days when submerged in phosphate-buffered saline
(PBS). Similarly, Lodoso-Torrecilla et al.16 evaluated the
effect of sucrose porogens, with or without PLGA porogens,
in a multimodal CPC-porogen system. Using a static in vitro
degradation study set-up, they showed rapid mass loss of
CPC-sucrose formulations. After 1 day of incubation in PBS
at 37C, this mass loss was already equivalent to the initial
mass of sucrose within the CPC-sucrose formulations,
suggesting complete sucrose dissolution. Further, the CPC-
porogen formulations containing PLGA porogens showed a
continuous gradual mass loss with the concomitant increase
in porosity until week 6 of incubation. Yet, they observed
that sucrose porogens already partially dissolved during the
setting reaction, leading to pores with a considerably smaller
diameter than the original sucrose particle size (i.e., size
decreased from ~400 to ~130 μm). Overall, the addition of
sucrose to CPC and CPC-PLGA composites generated a CPC
composite comprising the multimodal porogen platforms
with accelerated pore formation and enhanced degradability,
retaining injectable and cohesive properties.
We here evaluated the incorporation of multimodal
porogen platforms (i.e., PLGA, sucrose, or a combination
thereof) in CPC in terms of mechanical properties, dynamic
in vitro degradation, and in vivo performance in a rat femoral
defect model. We hypothesized that addition of sucrose por-
ogens would enhance early CPC degradation due to fast
porosity creation within the ceramic CPC matrix in contrast to
delayed hydrolytic PLGA porogen degradation. As such, it was
hypothesized that the addition of sucrose as a porogen to CPC
would enhance CPC degradation and bone regeneration.
MATERIALS AND METHODS
Materials
CPC consisted of 100% milled, pure α-TCP powder with a mean
particle size of ~4.0 μm (CAM Bioceramics B.V., Leiden, The
Netherlands). PLGA powder had a mean particle size of
~60μm, a molecular weight of 17kDa and was acid-terminated
and contained both a lactic and glycolic weight percentage of
50 (manufactured at Corbion Purac® B.V., Gorinchem, the Neth-
erlands) (Supporting Information Fig. S1A). Sucrose had a
mean particle size of ~400μm (Merck, Darmstadt, Germany)
(Supporting Information Fig. S1B). An 8 wt/vol% sodium
dihydrogen phosphate dihydrate (NaH2PO42H2O) aqueous
solution was used as liquid component to create the cement
paste and was made by dissolving 8.0 g of NaH2PO42H2O
(Merck) in 100mL Milli-Q water.
Preparation of samples for characterization and
dynamic degradation in vitro
CPC formulations were prepared according to the protocol
described by Lodoso-Torrecilla et al.16 Briefly, porogens
(i.e., sucrose and/or PLGA particles) were added to α-TCP
powder in various ratios as shown in Supporting Information
Table S1. For formulations containing PLGA, the ratio of CPC:
PLGA remained constant at a 60:40wt%. The addition of
sucrose remained constant at 20wt% of the total weight. This
is the maximum weight percentage that can be added to CPC,
retaining the handling properties required for clinical applica-
tions.16 An 8 wt/vol% aqueous solution of NaH2PO4 at differ-
ent liquid-to-powder ratios (LPR) was used. To prevent
premature sucrose dissolution, the aqueous solution had a
temperature of 4C. The liquid phase was added to the pow-
der phase and mixed vigorously for approximately 20 s. The
resulting paste was inserted into a mold made of poly-
tetrafluorethylene (PTFE) containing cylindrical holes, allowing
setting of the cement samples. For characterization, samples
were directly analyzed or incubated in 10 mL phosphate-
buffered saline (PBS, pH=7.4, Gibco®, Thermo Scientific, Wal-
tham, MA) at 37C and 120 rpm for 7 days to allow for phase
transformation. Elimination of residual liquid was accom-
plished by freeze-drying of the samples. Before performing the
dynamic degradation tests, samples were freeze-dried.
Sample characterization
The morphology of the CPCs before and after 1week of incu-
bation was visualized by scanning electron microscopy
(SEM, Zeiss Sigma 300), using a golden sputter coating for
the cement samples. Imaging was performed under high vac-
uum at an accelerating voltage of 3 kV. The compressive
strength of all CPC formulations was tested via placement in
a testing bench (Ametek, Lloyd instruments, Bognor Regis,
UK) and compression at a cross-head speed of 0.5 mm/min.
The compressive strength was measured before and after
7 days of incubation (n= 10). After mechanical testing, sam-
ples were ground to powder and analyzed by powder X-ray
diffraction (XRD; X’Pert3 Powder, PANalytical, Almelo, The
Netherlands) to determine the crystal phase of the cement
composites from 20 to 60 2θ with a step size of 0.02 2θ
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and a counting time of 1 s. An X-ray diffractogram of α-TCP
powder was used as control.
Set-up for testing the dynamic degradation in vitro
For the degradation studies, a dynamic flow system was
designed as described previously,20 with modifications. The
dynamic flow system consisted of a circuit formed by several
flow chambers with a cylindrical exterior (length=62mm, dia-
meter =30mm) and a cylinder-shaped interior (length=62mm,
diameter =11mm) made of polymethylmethacrylate (PMMA).
Four parallel circuits were used, one for each CPC formulation
studied. Each circuit consisted of two flow chambers, each one
containing two CPC samples, which were previously freeze-
dried. The flow chambers were connected using silicon tubes
(L/S® Precision Pump Tubing, Masterflex®, Metrohm Applikon
B.V., The Netherlands). For each group, an Erlenmeyer flask
filled with 300mL of PBS at 37C was used as medium reser-
voir. A peristaltic pump (EV045, Verderflex, Verder Liquids B.V.,
The Netherlands) was connected to the flow chambers and the
Erlenmeyer flask, which allowed PBS to flow through the sam-
ples at a rate of 1 mL/min. The dynamic flow systems were set
for 1, 2, 4, 6, and 8 weeks, and after each time point the samples
were taken out for further analysis and the flow system was
cleaned up and started for a new time point.
Analysis of samples subjected to dynamic degradation
in vitro
To quantify PLGA degradation, the pH of the PBS buffer was
analyzed directly after removal of the samples, using an elec-
trode (Orion, Sigma Aldrich) (n= 1). To quantify the mass
loss of the CPC samples (n= 4) as a function of time, sample
weight was measured before and after incubation in PBS
(i.e., after free-drying of the samples) and the remaining
material was calculated using Eq. (1).
% Remaining material = 100−
mi−mn
mi
*100% ð1Þ
mn represents sample mass at t = n (g) and mi represents
sample mass at t = 0 (g).
At each time point, calcium released into the PBS was
measured using the orthochresolphtalein complexone (OCPC)
method (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Nether-
lands) (n = 1).
Preparation of samples for the animal study
An 8 w/v% aqueous solution of NaH2PO4 of 4C was mixed
by spatula with one of the various combinations of α-TCP,
sucrose and/or PLGA (Supporting Information Table S1) and
inserted in a polytetrafluorethylene (PFTE) mold to allow
for hardening. The samples for in vivo implantation mea-
sured 2.5 mm in diameter and 5 mm in height. All samples
were sterilized by gamma irradiation at a minimum dose of
25 kGy (Synergy Health Ede, B.V., Ede, The Netherlands).
Animal model and surgical procedure
Thirty-two skeletally mature, male, Wistar rats with a weight
ranging from 200 to 250 g were used as experimental
animals (n = 8 per experimental group, per time-point). The
animals were housed at the Central Animal Laboratory,
(Radboudumc, Nijmegen, The Netherlands) with respect to
the national guidelines for the care and use of laboratory
animals, following the guidelines of the 2010/63/EU direc-
tive. The study was reviewed and approved in advance by the
Centrale Commissie Dierproeven (CCD; Central Commission
for Animal Experiments; CCD number AVD103002015227).
The rats underwent a one-session surgical procedure. Surgery
was performed under general inhalation anesthesia induced
by and maintained with a mixture of isoflurane and oxygen
through a constant volume ventilator. After induction of anes-
thesia, the rats were immobilized on their back. The surgical
sites were shaved and disinfected with povidone-iodine,
followed by sterile dressing. A longitudinal incision was made
medially from the patella and the patella was pushed aside.
Subsequently, the distal femur was made visual and the peri-
osteum was opened and bluntly dissected of the femoral bone.
Bone defects were created in the longitudinal direction of the
bone using a dental drilll, increasing the diameter of the bur
until a defect of 2.5 mm in diameter and 5 mm in depth was
reached (Supporting Information Fig. S2). Bone defects were
filled with the various pre-set cement samples (Supporting
Information Fig. S2). The patella was pushed back in place
and the subcutaneous tissue was closed with resorbable sin-
gle sutures (Vicryl 4.0, Ethicon, NJ). The skin was closed with
staples. Materials were allocated over the 64 defects by means
of randomization with respect to the fact that the right en
left femur would contain different experimental materials.
Carprofen (Rimadyl®, Zoetis B.V., Capelle aan de IJssel, The
Netherlands;) was administered prior to surgery and for
3 days post surgery to reduce postoperative pain and
decrease inflammatory response. Implantation periods were
2 and 8 weeks. The animals were sacrificed by an overdose of
CO2. After euthanasia, femora were retrieved, excess soft tis-
sue was removed, and excess bone was cut off with a diamond
blade saw.
Histological procedures
Fixation of specimens was carried out in a 4% phosphate-
buffered formaldehyde solution (pH 7.2), after which the
specimens were dehydrated in graded series of ethanol
concentrations (70–100%) and embedded in PMMA. After
polymerization, thin sections of 10 μm were prepared in a
cross-sectional direction perpendicular on the longitudinal
direction of the bone defect using a saw microtome with a
diamond blade (Leica SP 1600, Leica Biosystems Nussloch
GmbH, Nussloch, Germany). The sections were stained with
methylene blue and basic fuchsine.
Histological and histomorphometric analysis
Histological evaluation of three sections of each sample
(n= 3) was performed using a light microscope (Leica Micro-
systems AG, Wetzlar, Germany). Histomorphometric analysis
of the bone sections was performed by evaluating the region
of interest (ROI) of these sections. To this end, a circle of
2.45mm in diameter was superimposed over the histological
image and centered in the middle of the filled bone defect
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(Supporting Information Fig. S3). In samples where CPC had
undergone degradation, bone morphology was assessed in
order to align the ROI to the border of the defect site
(Supporting Information Fig. S3c). The relative area of mate-
rial remnants and bone tissue (based on staining and
morphology) was quantified using image analysis software
(ImageJ2, National Institutes of Health, Bethesda, MD). Mate-
rial degradation was expressed as the percentage of material
remnants in the region of interest (ROI).
Statistical analysis
Data are presented as mean standard deviation (SD) for all
experimental set-ups (i.e., in vitro and in vivo). For all
in vitro experiments, sample sizes as described in this exper-
imental section were used for statistical analyses. For the
in vivo experiment, eight samples of each experimental
group (n = 8) were used for statistical analyses after 2weeks
of implantation. After 8weeks, sample size varied per experi-
mental group (CPC [n= 7]; CPC-sucrose [n = 7]; CPC-PLGA
[n= 6]; CPC-PLGA-sucrose [n = 8]) (Supporting Information
Table S2). A Kruskal-Wallis test with a Dunn’s multiple com-
parison post-hoc test was used to identify significant differ-
ences between CPC and CPC-sucrose and between CPC-PLGA
and CPC-PLGA-sucrose in all experimental set-ups in vitro
and in vivo. A Mann–Whitney test was used to identify sig-
nificant differences in vivo from 2 to 8weeks for all groups
individually. Results were considered significant at p < 0.05.
Statistical analyses were performed with GraphPad Prism
7 (GraphPad Software Inc., San Diego, CA).
RESULTS
Characterization of CPC formulations
SEM images (Supporting Information Fig. S4) were taken
before and after 1 week of incubation. The images revealed
that the CPC matrix and PLGA particles remained intact dur-
ing the first week of incubation. Sucrose particles, on the
other hand, were completely dissolved.
The mechanical properties of the different CPC formulations
were studied by means of their compressive strength (Fig. 1A).
For non-incubated samples, it was observed that pure CPC had
a compressive strength of 12.2 1.8 MPa, while addition of
sucrose porogens to CPC significantly decreased the compres-
sive strength to 6.9 1.5 MPa (p<0.05). Non-incubated CPC-
PLGA had a compressive strength of 6.0 1.2 MPa. Addition of
sucrose to CPC-PLGA significantly decreased the compressive
strength to 3.7 0.9 MPa (p<0.05).
After 7 days of incubation in PBS, CPC had a compressive
strength of 17.4 2.8 MPa. Compared to CPC, addition of
sucrose significantly decreased the compressive strength to
10.9 2.2 MPa (p<0.05). CPC-PLGA and CPC-PLGA-sucrose
showed similar values for compressive strength (9.9 2.1 MPa
and 7.70.8 MPa, respectively; p>0.05). All the groups pres-
ented a significantly higher compressive strength after 7 days
of incubation compared to before incubation (p≤0.0001 for
all formulations).
Figure 1B shows the powder XRD-patterns of CPC pre-
incubation and all CPC-porogen formulations after 7 days of incu-
bation. XRD of CPC preincubation shows the main diffraction
peaks of α-TCP.21 XRD of the different CPC-porogen formulations
after 7 days of incubation shows similar patterns for all formula-
tions, with the main diffraction peaks of hydroxyapatite (HA),22
indicating the transition of α-TCP to HA after 7 days of incubation
for all formulations.
Dynamic degradation in vitro
In vitro degradation was studied using a dynamic degradation
set up (Fig. 2A). Degradation was evaluated using mass loss
and pH measurements during 8weeks of incubation (Fig. 2B
and C, respectively). After 1 week of incubation, CPC and CPC-
PLGA showed a slight increase in mass (increase of 4.2 1.0%
and 2.6 0.1%, respectively). CPC-sucrose showed a signifi-
cantly higher mass loss compared to CPC (mass loss of
13.4 0.9% for CPC-sucrose; p<0.001). CPC-PLGA-sucrose
showed similar values compared to CPC-sucrose (mass loss of
12.3 1.6% for CPC-PLGA-sucrose; p>0.05).
After 8 weeks of incubation, CPC-sucrose (mass loss of
17.5 3.4%) showed a significantly higher mass loss com-
pared to CPC (increase in mass of 1.4 0.1%; p < 0.001).
PLGA porogens induced mass loss after 8 weeks of incuba-
tion, both in CPC-PLGA and CPC-PLGA-sucrose composites
(mass loss of 3.6 0.4% and 22.4 1.0%, respectively).
FIGURE 1. (A) Characterization of CPC formulations. Compressive
strength (MPa) of the different CPC-porogen formulations upon setting
(n=10) (*p<0.05; error bars represent standard deviation (SD); Kruskal-
Wallis test with a Dunn’s multiple comparison post-hoc test) and
(B) XRD patterns of α-TCP powder (control) and the different CPC-
porogen formulations after 7 days of incubation, showing transition of
α-TCP (1) to hydroxyapatite (HA; 2) upon immersion in aqueous solu-
tion for all formulations.
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PLGA degradation induced a similar mass loss of ~5% in the
PLGA-containing groups when compared to their PLGA-free
counterparts.
Regarding pH measurements (Fig. 2C), CPC and different
CPC-porogen formulations showed a similar profile, with a
continuous decrease in pH from 7.4 to ~7 after 6 weeks of
incubation in PBS. Figure 2D shows the calcium concentra-
tion in mg/L for CPC and the different CPC-porogen formula-
tions during incubation in PBS. All formulations presented a
similar release pattern, with an initial calcium release at
week 1 of incubation of ~6–7 mg/L; which represents the
~3–4% of total calcium existent in the samples before incu-
bation. The calcium concentration remained relatively stable
over incubation time.
General evaluation of surgical procedures and animals
The surgical procedure was uneventful for all animals and
mobility was regained within 1 day after surgery without the
occurrence of wound complication. At each time point (i.e., 2
and 8 weeks), 18 rats were sacrificed, from which in total
72 specimens were retrieved. Of these, four specimens were
excluded for histological analyses due to inferior staining
quality. An overview of the number of implants that were
placed, retrieved, and analyzed per experimental group is
presented in Supporting Information Table S2.
Descriptive histology 2week implantation period
The left panels of Figure 3 present a histological overview of
all CPC-formulations after 2weeks of implantation. Implant
integrity was maintained for the implants of all experimental
CPC formulations. For CPC, no signs of material degradation
were observed. CPC-sucrose showed large pores, surrounded
by CPC with a dense appearance. For CPC-sucrose, a thin layer
of bone was observed in pores located at the implant periph-
ery. CPC-PLGA and CPC-PLGA-sucrose had a porous appear-
ance. Presence of PLGA porogen could not be evidently
distinct from presence of pores as a result of PLGA porogen
degradation. For CPC-PLGA-sucrose, large pores were visible
within the ceramic CPC matrix. These pores were not homo-
geneously distributed. No fibrous tissue was observed within
or in the vicinity of the experimental implants.
Descriptive histology 8week implantation period
The right panels of Figure 3 present a histological overview
of all CPC-formulations after 8weeks of implantation. CPC
and CPC-sucrose showed an irregular border as a result of
FIGURE 2. (A) Schematic representation of the dynamic flow system used for in vitro degradation studies. For each CPC formulation, four samples
were used in serial configuration (two per flow chamber) and a single peristaltic pump. (B) Mass loss of CPC formulations over incubation time
(n=4) (*p<0.05; error bars represent standard deviation (SD); Kruskal-Wallis test with a Dunn’s multiple comparison post-hoc test). (C) pH of the
incubation medium (PBS) over incubation time (n=1). (D) Ca2+ concentration (mg/L) in the incubation medium (PBS) over incubation time (n=1)
(error bars represent standard deviation [SD]).
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marginal peripheral material degradation. New bone forma-
tion was observed at the periphery of the experimental
implants, while the center of the defect still contained
ceramic CPC matrix. For CPC-sucrose, newly formed bone
was observed in the pores. A substantial decrease in mate-
rial remnants was observed for CPC-PLGA as well as for
CPC-PLGA-sucrose. For these CPC-porogen formulations,
remnants were diffusely distributed throughout the defect
area. New bone formation was observed in the areas of the
degraded material, at the periphery of the defect, and in the
center.
Histomorphometric results concerning material
degradation
Histomorphometric results concerning material degradation
are presented in Figure 4A. In 2weeks, CPC (89.514.6%)
FIGURE 3. Histological overview and magnifications of CPC formulations implanted in a rat femoral bone defect at two (left panels) and 8 weeks
(right panels). Sucrose porogen and PLGA porogen or pores resulting from sucrose porogen dissolution (large) or PLGA porogen degradation
(small) can be discriminated based on size differences. Large pores resulting from sucrose porogen dissolution are not homogeneously distributed.
At 2 weeks, limited tissue infiltration in peripheral pores resulting from sucrose porogen dissolution is apparent. At 8 weeks, significant degradation
of PLGA-containing CPC formulations can be observed. Pure CPC shows hardly any degradation over the entire implantation period.
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showed similar material remnant values compared to CPC-
sucrose (84.812.9%; p > 0.05). CPC-PLGA (50.0 25.5%)
showed similar material remnant values compared to CPC-
PLGA-sucrose (64.0 19.5%; p > 0.05).
In 8weeks, CPC (80.329.9%) showed similar material
remnant values compared to CPC-sucrose (71.1 38.8%;
p>0.05). CPC-PLGA (20.9 7.7%) showed similar material
remnant values compared to CPC-PLGA-sucrose (26.8 19.4%;
p>0.05). From 2 to 8weeks, CPC-PLGA and CPC-PLGA-sucrose
showed a significant decrease in material remnant values
(p=0.03 and p=0.007, respectively), while for CPC and CPC-
sucrose material remnant values were similar at 2 and
8weeks (p>0.05).
Histomorphometric results concerning bone formation
Histomorphometric results concerning new bone formation
are presented in Figure 4B. In 2weeks, CPC (0 0%)
showed a similar amount of new formed bone compared to
CPC-sucrose (0.10.1%; p > 0.05). CPC-PLGA (5.0 8.6%)
showed a similar amount of newly formed bone compared
to CPC-PLGA-sucrose (0.3 0.8% p > 0.05).
In 8weeks, CPC (4.5 6.9%) showed a similar amount of
new formed bone compared to CPC-sucrose (7.7 11.4%;
p > 0.05). CPC-PLGA (18.6 11.1%) showed a similar
amount of new formed bone compared to CPC-PLGA-sucrose
(21.2 11.7%; p > 0.05). From 2 to 8weeks, CPC-PLGA and
CPC-PLGA-sucrose showed a significant increase in new
bone formation (p = 0.01 and p < 0.002, respectively), while
for CPC and CPC-sucrose new bone formation was similar at
2 and 8weeks (p > 0.05).
DISCUSSION
We here evaluated multimodal porogen platforms for incor-
poration within CPC to introduce porosity within the ceramic
CPC matrix and accelerate material degradation and bone
formation. In vitro, we assessed the mechanical properties
and dynamic degradation characteristics of the different
CPC-porogen formulations. Furthermore, we performed an
in vivo study to evaluate the biological performance of the
different CPC-porogen formulations in terms of degradation
and concomitant bone formation. We hypothesized that the
inclusion of sucrose porogens in CPC would accelerate early
stage material degradation and bone regeneration due to fast
porogen dissolution. Additionally, we hypothesized that late
stage degradation and bone formation would be enhanced
by (delayed) hydrolytic degradation of PLGA porogens and
the acidifying effects of the degradation products thereof on
the ceramic CPC matrix. The experimental data showed that
inclusion of sucrose porogens decreased the initial compres-
sive strength of the CPC and induced an early in vitro mass
loss equal to the quantity of sucrose. Further, the addition of
sucrose did not alter the crystallographic profile. Upon appli-
cation as a bone substitute material in a rat femoral bone
defect model, no additional effects were observed from the
incorporation of sucrose porogens in CPC or CPC-PLGA.
Compressive strength measurements for the different
CPC formulations upon setting showed that the inclusion of
sucrose porogens significantly decreased the initial compres-
sive strength (i.e., before incubation in PBS), while the com-
pressive strength of CPC-PLGA-sucrose was similar to that of
CPC-PLGA after 7 days of incubation in PBS. In general, it
has been widely reported that the inclusion of porogens in
CPCs, and the subsequent creation of a macroporous ceramic
structure, reduces the mechanical properties of CPCs.11,23,24
Zhang et al. evaluated around 20 different studies and
observed a negative correlation between the porosity per-
centage in CPCs and their compressive strength.24 On the
other hand, all CPC formulations showed significantly higher
compressive strength after incubation in PBS for 7 days due
to the phase transformation from α-TCP to hydroxyapatite,
as confirmed by XRD results.25 Furthermore, it is important
to take into account that in vivo, sucrose will dissolve within
the first day and, subsequently, the mechanical properties of
the CPC might become temporarily negatively affected until
the phase transformation occurs.26
In order to test new pore-forming additives for enhan-
cement of CPC degradation, in vitro degradation studies
are commonly performed. While most studies analyze the
FIGURE 4. Histomorphometrical quantification of material remnants
(A) and new formed bone (B) in the region of interest (ROI) for CPC-
sucrose, CPC-PLGA, CPC-PLGA-sucrose and CPC after two (n=8) and
8weeks (n=7, n=6, n=8, and n=7, respectively) of implantation in a
rat femoral bone defect (error bars represent standard deviation [SD]).
(*p<0.05; error bars represent standard deviation [SD]; Kruskal-Wallis
test with a Dunn’s multiple comparison post-hoc test).
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in vitro degradation using a static set up (where the samples
are introduced in a soaking medium without any mechanical
stirring or fluid flow),10,27,28 others use a dynamic set up
(where the samples are incubated under a dynamic flow of
medium).20,29,30 It has been speculated that dynamic set-ups
are more biomimetic than static set-ups.20,29 For CPC-PLGA
constructs, most in vitro studies performed to data have
used a static set up with sample incubation in a small
amount of soaking medium, which magnifies the acidification
effect related to PLGA degradation on the ceramic matrix of
the CPC.10,16,31 On the other hand, dynamic degradation set-
ups commonly use higher amounts of soaking medium,
which, together with the continuous fluid flow, act as a
buffer and the PLGA-related acidification only has a minor
local effect, similar to the in vivo situation.20,29 In view of
this, we used a dynamic set up to study in vitro degradation
of the different CPC formulations during 8 weeks. As hypoth-
esized, sucrose dissolution occurred at an early stage while
PLGA degradation did not occur until approximately 6 to
8 weeks of incubation. In previous research,16 using a static
degradation set-up the dissolution of sucrose also occurred
within the first week of incubation, but PLGA degradation
started at an earlier time point (i.e., after approximately
2 weeks of incubation). This difference between dynamic
and static set-ups was also observed by An et al. and
Agrawal et al.,20,29 which is likely due to the accelerating
effect of a lower pH on PLGA degradation. This higher acidi-
fication in static set-ups is related to both the difference in
soaking medium amounts used (up to 10 mL in static vs. up
to 300mL in dynamic) and the buffering effect of the fluid
flow created in the dynamic set up.
Based on the results of the in vitro studies, two different
implantation periods of 2 and 8 weeks were selected. Similar
to previous studies, 2 weeks was selected as an early stage
implantation time point to observe the effect of sucrose
porogen dissolution on pore formation, material degradation,
and bone formation.32,33 In contrast, effects of PLGA degra-
dation on these aspects were expected after a prolonged
implantation (e.g., 8 weeks).19,32,33 Indeed, CPC implants
containing sucrose porogens showed the presence of large
pores within the ceramic CPC matrix after 2 weeks of
implantation. This observation matches the in vitro dynamic
dissolution study, where it was observed that after 1 week
of incubation the sucrose was fully dissolved. However,
while in vitro results showed that PLGA starts degrading
after 6–8 weeks of incubation, in vivo results showed other-
wise. Here, PLGA started degrading after 2 weeks of implan-
tation, similar to what was observed by Renno et al.,33 and
after 8 weeks only ~20% of the material was remaining. On
the other hand, static in vitro data previously revealed that
PLGA dissolution started after 2 weeks of incubation, which
more closely correlates with the in vivo situation.16
A limitation of this study is not being able to fully dis-
tinct between non-degraded PLGA porogen and pores as a
result of PLGA porogen degradation. We quantified the rela-
tive area of material remnants (i.e., the amount of CPC)
based on staining and morphology. According to previous
studies,9,32,33 the porous appearance in the formulations
containing PLGA at 2weeks, should correspond to non-
degraded PLGA porogen. As a result, measurements of mate-
rial remnants in the PLGA-containing formulations might be
underestimated.
While sucrose dissolution occurred at an early stage in the
dynamic degradation set up in vitro, sucrose porogens did not
improve the biological performance of CPC or CPC-PLGA in
terms of early material degradation and concomitant bone
formation. Regarding this discrepancy, the influence of parti-
cle size and manner of disappearance of both porogen plat-
forms should be considered. In this study, PLGA particles had
a mean particle size of ~60 μm and sucrose particles had a
mean particle size of ~400 μm. PLGA particles disappear upon
hydrolytic degradation, creating an acidic environment which
accelerates the degradation of the CPC matrix,8,34 increasing
pore size compared to initial particle size. Sucrose particles
on the other hand, disappear upon dissolution. Previous
work16 showed that sucrose particles suffer partial dissolu-
tion during the process of cement setting, starting when the
liquid component is added to the powder component. The
consequences of premature particle dissolution are a
decreased pore size compared to initial particle size and a
decreased weight percentage of sucrose available to form
macropores after setting. It was previously described that to
generate an interconnected pore structure, the volume frac-
tion of porogens should exceed 40%.12,15 Del Real et al.35
stated that CaP ceramics should have interconnective pores
with a diameter larger than 100 μm to allow for active resorp-
tion throughout the CaP matrix. A clear effect of the loading
amount and size of PLGA porogen on interconnectivity within
CPC was observed by Lopez-Heredia et al.11 using intercon-
nectivity μ-CT analysis. They observed that an increased parti-
cle size might reduce the loading amount without a change in
interconnectivity, although general porosity of CPC would be
increased by the use of smaller particles, generating faster
resorption. Previous in vivo studies showed the influence of
particle size of PLGA porogen on the biological performance
of CPC. Liao et al.36 observed significant effects on the biologi-
cal performance of CPC-PLGA by altering the size of hollow
PLGA microspheres. CPC with small, hollow microspheres
showed a twofold higher bone formation compared to large,
hollow microspheres after 12weeks of implantation. Hoekstra
et al.37 found no effect of dense PLGA microsphere size on
material degradation and bone formation after 12weeks of
implantation. For CPC containing the sucrose porogen plat-
form, an improvement in pore interconnectivity would enable
fluid flow throughout the material and hence active material
degradation. In view of this, smaller porogens would be pref-
erable for the sucrose porogen platform, because of the
increase in interconnectivity when homogeneously distrib-
uted. Ideally, dissolution of sucrose porogens should be
delayed (e.g., by cooling the liquid component used for CPC
preparation) until initial CPC setting has occurred.
CONCLUSION
Inclusion of the sucrose porogen platform in CPC decreased
the compressive strength of CPC and induced an early
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in vitro mass loss proportional to the amount of sucrose.
Inclusion of the sucrose porogen platform in CPC-PLGA did
not decrease the compressive strength of CPC-PLGA after
7 days of incubation and did not affect in vitro mass loss.
Evaluation of the biological performance in a rat femoral
bone defect showed that inclusion of the sucrose porogen
platform in CPC or CPC-PLGA had no additional effects in
terms of early degradation or additional bone formation.
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